Dupont Capital Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-9,162
| Closed | -$760K | – | 665 |
|
|
2023
Q1 | $760K | Sell |
9,162
-3,035
| -25% | -$251K | 0.04% | 253 |
|
|
2022
Q4 | $1.05M | Buy |
12,197
+2,403
| +25% | +$190K | 0.05% | 315 |
|
|
2022
Q3 | $604K | Buy |
9,794
+389
| +4% | +$24.5K | 0.04% | 563 |
|
|
2022
Q2 | $581K | Sell |
9,405
-1,509
| -14% | -$93.4K | 0.03% | 648 |
|
|
2022
Q1 | $649K | Sell |
10,914
-4,154
| -28% | -$266K | 0.03% | 663 |
|
|
2021
Q4 | $1.09M | Sell |
15,068
-7,694
| -34% | -$530K | 0.04% | 469 |
|
|
2021
Q3 | $1.59M | Sell |
22,762
-26,064
| -53% | -$1.83M | 0.05% | 390 |
|
|
2021
Q2 | $3.36M | Buy |
48,826
+9,858
| +25% | +$658K | 0.08% | 219 |
|
|
2021
Q1 | $2.52M | Buy |
38,968
+11,257
| +41% | +$726K | 0.06% | 272 |
|
|
2020
Q4 | $1.61M | Sell |
27,711
-1,848
| -6% | -$112K | 0.03% | 395 |
|
|
2020
Q3 | $1.87M | Sell |
29,559
-4,791
| -14% | -$332K | 0.04% | 326 |
|
|
2020
Q2 | $2.64M | Sell |
34,350
-14,855
| -30% | -$1.14M | 0.06% | 250 |
|
|
2020
Q1 | $3.68M | Buy |
49,205
+7,808
| +19% | +$540K | 0.09% | 167 |
|
|
2019
Q4 | $2.69M | Buy |
41,397
+5,076
| +14% | +$331K | 0.06% | 283 |
|
|
2019
Q3 | $2.3M | Sell |
36,321
-4,977
| -12% | -$325K | 0.05% | 304 |
|
|
2019
Q2 | $2.79M | Buy |
41,298
+14,301
| +53% | +$941K | 0.06% | 293 |
|
|
2019
Q1 | $1.75M | Buy |
26,997
+8,719
| +48% | +$580K | 0.04% | 399 |
|
|
2018
Q4 | $1.14M | Sell |
18,278
-11,321
| -38% | -$791K | 0.03% | 496 |
|
|
2018
Q3 | $2.29M | Buy |
29,599
+14,252
| +93% | +$1.08M | 0.05% | 345 |
|
|
2018
Q2 | $1.09M | Sell |
15,347
-2,103
| -12% | -$149K | 0.03% | 535 |
|
|
2018
Q1 | $1.32M | Sell |
17,450
-25,452
| -59% | -$2.02M | 0.03% | 436 |
|
|
2017
Q4 | $3.07M | Sell |
42,902
-212,183
| -83% | -$16.1M | 0.07% | 255 |
|
|
2017
Q3 | $20.7M | Buy |
255,085
+15,009
| +6% | +$1.15M | 0.47% | 35 |
|
|
2017
Q2 | $17M | Buy |
240,076
+23,964
| +11% | +$1.59M | 0.38% | 48 |
|
|
2017
Q1 | $14.7M | Sell |
216,112
-31,952
| -13% | -$2.25M | 0.33% | 49 |
|
|
2016
Q4 | $17.8M | Sell |
248,064
-31,799
| -11% | -$2.36M | 0.4% | 41 |
|
|
2016
Q3 | $22.1M | Sell |
279,863
-50,613
| -15% | -$4.11M | 0.5% | 28 |
|
|
2016
Q2 | $27.6M | Sell |
330,476
-37,825
| -10% | -$3.36M | 0.61% | 21 |
|
|
2016
Q1 | $33.8M | Buy |
368,301
+11,886
| +3% | +$1.07M | 0.77% | 10 |
|
|
2015
Q4 | $36.1M | Sell |
356,415
-49,562
| -12% | -$5.16M | 0.87% | 12 |
|
|
2015
Q3 | $39.9M | Sell |
405,977
-76,287
| -16% | -$8.47M | 1.01% | 10 |
|
|
2015
Q2 | $56.5M | Buy |
482,264
+14,451
| +3% | +$1.58M | 1.22% | 6 |
|
|
2015
Q1 | $45.9M | Sell |
467,813
-92,809
| -17% | -$9.42M | 0.9% | 16 |
|
|
2014
Q4 | $52.8M | Buy |
560,622
+275,212
| +96% | +$28.5M | 0.97% | 18 |
|
|
2014
Q3 | $30.4M | Buy |
285,410
+49,149
| +21% | +$4.81M | 0.53% | 36 |
|
|
2014
Q2 | $19.6M | Buy |
236,261
+201,823
| +586% | +$15.7M | 0.32% | 63 |
|
|
2014
Q1 | $2.44M | Buy |
34,438
+8,151
| +31% | +$639K | 0.04% | 325 |
|
|
2013
Q4 | $1.98M | Sell |
26,287
-13,255
| -34% | -$923K | 0.03% | 359 |
|
|
2013
Q3 | $2.48M | Sell |
39,542
-16,830
| -30% | -$1.01M | 0.05% | 323 |
|
|
2013
Q2 | $2.89M | Buy |
+56,372
| New | +$2.94M | 0.05% | 296 |
|
Other funds holding GILD
Dupont Capital Management's GILD Position: Q2 2023 in Review
Dupont Capital Management sold out of Gilead Sciences (GILD) in Q2 2023, closing a stake of 9,162 shares — an estimated $760K sold.
Dupont Capital Management first reported a position in GILD in Q2 2013 and held it in 40 quarters. The position peaked at $56.5M in Q2 2015. 1,702 funds tracked by Wall St. Rank hold GILD as of Q2 2023.
- Dupont Capital Management reported no remaining Gilead Sciences position as of Q2 2023 after selling out during the quarter.
- Dupont Capital Management sold 9,162 Gilead Sciences shares in Q2 2023, an estimated $760K.
- Dupont Capital Management first reported a position in Gilead Sciences in Q2 2013 and held it in 40 quarters.
- Dupont Capital Management's Gilead Sciences position peaked at $56.5M in Q2 2015.
- 1,702 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2023.
Based on Dupont Capital Management's 13F filing for Q2 2023, filed 25 Jul 2023.